A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy

Trial Profile

A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Emricasan (Primary)
  • Indications Hepatic fibrosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms POLT-HCV-SVR
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to a Conatus Pharmaceuticals media release, top-line results from this trial are expected in the second quarter of 2018.
    • 05 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Feb 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top